569 related articles for article (PubMed ID: 21030620)
41. Epigenetic therapy--a new development in pharmacology.
Peedicayil J
Indian J Med Res; 2006 Jan; 123(1):17-24. PubMed ID: 16567863
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
43. DNA methyltransferase inhibitors: an updated patent review (2012-2015).
Xu P; Hu G; Luo C; Liang Z
Expert Opin Ther Pat; 2016 Sep; 26(9):1017-30. PubMed ID: 27376512
[TBL] [Abstract][Full Text] [Related]
44. Epigenetic drug discovery: targeting DNA methyltransferases.
Foulks JM; Parnell KM; Nix RN; Chau S; Swierczek K; Saunders M; Wright K; Hendrickson TF; Ho KK; McCullar MV; Kanner SB
J Biomol Screen; 2012 Jan; 17(1):2-17. PubMed ID: 21965114
[TBL] [Abstract][Full Text] [Related]
45. Epigenetic modulators as therapeutic targets in prostate cancer.
Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
[TBL] [Abstract][Full Text] [Related]
46. Review-Epigenetic therapy for cancer.
Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
[TBL] [Abstract][Full Text] [Related]
47. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
48. DNA Methyltransferase Inhibitors and their Therapeutic Potential.
Zhou Z; Li HQ; Liu F
Curr Top Med Chem; 2018; 18(28):2448-2457. PubMed ID: 30465505
[TBL] [Abstract][Full Text] [Related]
49. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
Rondelet G; Wouters J
Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
[TBL] [Abstract][Full Text] [Related]
50. The clinical application of targeting cancer through histone acetylation and hypomethylation.
Gilbert J; Gore SD; Herman JG; Carducci MA
Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
[TBL] [Abstract][Full Text] [Related]
51. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
Fandy TE; Carraway H; Gore SD
Cancer J; 2007; 13(1):40-8. PubMed ID: 17464245
[TBL] [Abstract][Full Text] [Related]
52. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
53. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic regulation: a new research area for melatonin?
Korkmaz A; Reiter RJ
J Pineal Res; 2008 Jan; 44(1):41-4. PubMed ID: 18078446
[TBL] [Abstract][Full Text] [Related]
55. Epigenetic small molecule modulators of histone and DNA methylation.
Hauser AT; Robaa D; Jung M
Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
[TBL] [Abstract][Full Text] [Related]
56. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
57. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
59. Epigenetics in radiotherapy: where are we heading?
Smits KM; Melotte V; Niessen HE; Dubois L; Oberije C; Troost EG; Starmans MH; Boutros PC; Vooijs M; van Engeland M; Lambin P
Radiother Oncol; 2014 May; 111(2):168-77. PubMed ID: 24861629
[TBL] [Abstract][Full Text] [Related]
60. What is the potential of epigenetics in drug development?
Lundstrom K
Future Med Chem; 2015; 7(3):239-42. PubMed ID: 25826357
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
